|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Quantification of mRNA degradation as possible indicator of post- mortem interval-a pilot study显示文摘 | Bauer M Gramlich I Polzin S | 2003 | Leg Med(Tokyo)2003，5，4： | 1 |
| 2 | Quantification of mRNA degradation as possible indicator of postmortem interval--a pilot study显示文摘 | BAUER M GRAMLICH I POLZIN S | 2003 | Leg Med (Tokyo)2003，5，4： | 1 |
| 3 | Quantification of mRNA degradation as possible indicator of postmortem interval a pilot study 显示文摘 | Bauer M Gramlich I Polzin S | 2003 | Leg Med2003，5，4： | 1 |
| 4 | Quantification of mRNA degradation as possible indicator of postmortem interval-a pilot study显示文摘 | Bauer M Gramlich I Polzin S | 2003 | Leg Med2003，5，4： | 1 |
| 5 | Novel, Highly Nonlinear Optical Molecular Crystals Based on Multidonor-Substituted 4-Nitrophenylhydrazones显示文摘 | Liakatas I Wong M S Gramlich V | 1998 | Adv Mater1998，10，： | 1 |
| 6 | Quantification of mRNA degradation as possible indicator of postmortem interval-a pilot study显示文摘 | Bauer M Gramlich I Polzin S | 2003 | Leg Med(Tokyo)2003，5，4： | 1 |
| 7 | Quantification of mRNA degradation as possible indicator of postmortem intervala pilot study显示文摘 | Bauer M Gramlich I Polzin S | | 0，，05： | 1 |
| 8 | Novel, High Nonlinear Optical Molecular Crystals Based on MultidonorSubstituted 4-Nitrophenylhydrazones显示文摘 | Wong M S Gramlich V | 1998 | Advanced Materials1998，10，： | 1 |
| 9 | Quantification of mRNA degradation as possible indicator of postmortem interval - a pilot study 显示文摘 | Bauer M Gramlich I Polzin S | 2003 | Leg Med (Tokyo)2003，5，4： | 1 |
| 10 | Quantification of mRNA degradation as possible indicator of postmortem interval--a pilot study显示文摘 | Bauer M Gramlich I Polzin S | 2003 | Legal Med (Tokyo)2003，5，4： | 1 |
| 11 | Quantification of mRNA degradation as possible indicator of postmortem interval-a pilot study 显示文摘 | Bauer M Gramlich I Polzin S | 2003 | Leg Med2003，5，4： | 1 |
| 12 | Quantification of mRNA degradation as possible indicator of postmortem intervala pilot study显示文摘 | Bauer M Gramlich I Polzin S | | 0，，05： | 1 |
| 13 | A treatment algorithm for neuropathic pain显示文摘 | Namaka M Gramlich CR Ruhlen D Melanson M Sutton I Major J | | 0，，： | 1 |
| 14 | Improved canine model for laryngotracheal stenosis显示文摘 | Eliashar R Elisehar I Gramlich T | 2000 | Otolaryngol Head Neck Surg2000，122，1： | 1 |
| 15 | Quantification of mRNA degradation as possible indicator of postmortem interval-a pilot study显示文摘 | Bauer M Gramlich I Polzin S | 2003 | Leg Med(Tokyo)2003，5，4： | 1 |
| 16 | Quantification of mRNA degradation as possible indicator of postmortem interval a pilot study 显示文摘 | Bauer M Gramlich I Polzin S | 2003 | Leg Med2003，5，4： | 1 |
| 17 | Quantification of mRNA degradation as possible indicator of postmortem interval - a pilot study显示文摘 | Bauer M Gramlich I Silke Patzelt D | 2003 | Leg Med2003，5，4： | 1 |
| 18 | Use of parenteral nutrition in patients with advanced cancer显示文摘 | Soo I Gramlich L | 2008 | Appl Physiol Nutr Metab2008，33，1： | 1 |
| 19 | Improved canine model for laryngotracheal stenosis显示文摘 | Eliashar R Eliachar I Gramlich T | 2000 | Otolaryngol Head Neck Surg2000，122，： | 1 |
| 20 | Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation显示文摘AIM:To investigate genetic differences between Crohn's disease(CD) patients with a sustained remission vs relapsers after discontinuing infliximab while in corticosteroid-free remission.METHODS:Forty-eight CD patients received infliximab and were in full corticosteroid-free clinical remission but then discontinued infliximab for reasons other than a loss of response,were identified by review of an electronic database and charts.Infliximab-associated remission was defined as corticosteroid-free plus normalization of clinical disease activity [CD activity index(CDAI) < 150] during follow-up visits based on physician global assessments.A CD relapse(loss of infliximab-induced remission) was clinically defined as a physician visit for symptoms of disease activity(CDAI > 220) and a therapeutic intervention with CD medication(s),or a hospitalization with complications related to active CD.Genetic analyses were performed on samples from 14 patients(n = 6 who had a sustained long term remission after stopping infliximab,n = 8 who rapidly relapsed after stopping infliximab).Nucleotide-binding oligomerization domain 2(NOD2)/caspase activation recruitment domain 15(CARD15) polymorphisms(R702W,G908R and L1007fs) and the inflammatory bowel disease 5(IBD5) polymorphisms(IGR2060a1 and IGR3081a1) were analyzed in each group.RESULTS:Five single nucleotide polymorphisms of IBD5 and NOD2/CARD15 genes were successfully analyzed for all 14 subjects.There was no significant increase in frequency of the NOD2/CARD15 polymorphisms(R702W,G908R and L1007fs) and the IBD5 polymorphisms(IGR2060a1 and IGR3081a1) in either group of patients;those whose disease relapsed rapidly or those who remained in sustained long term remission following the discontinuation of infliximab.Nearly a third of patients in full clinical remission who stopped infliximab for reasons other than loss of response remained in sustained clinical remission,while two-thirds relapsed rapidly.There was a marked difference in the duration of clinical remission following discontinuance of infliximab between the two groups.The patients who lost remission did so after 1.0 years ± 0.6 years,while those still in remission were at the time of this study,8.1 years ± 2.6 years post-discontinuation of infliximab,P < 0.001.The 8 patients who had lost remission after discontinuing infliximab had a mean number of 5 infusions(range 3-7),with a mean treatment time of 7.2 mo(range 1.5 mo-15 mo).The mean duration of time from the last infusion of infliximab to the time of loss of remission was 382 d(range 20 d-701 d).The 6 patients who remained in remission after discontinuing infliximab had a mean number of 6 infusions(range 3-12),with a mean treatment duration of 12 mo(range 3.6 mo-32 mo)(P = 0.45 relative to those who lost remission).CONCLUSION:There are no IBD5 or NOD2/CARD15 mutations that predict which patients might have sustained remission and which will relapse rapidly after stopping infliximab. | Cathy Lu Alistair Waugh Robert J Bailey Raeleen Cherry Levinus A Dieleman Leah Gramlich Kata Matic Mario Millan Karen I Kroeker Daniel Sadowski Christopher W Teshima Dennis Todoruk Clarence Wong Karen Wong Richard N Fedorak | 2012 | World Journal of Gastroenterology2012，18，36： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员